Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otelixizumab

Next Previous
X
Search
Drug Profile

Otelixizumab

Alternative Names: ChAglyCD3; GSK-2136525; Humanised anti-CD3 monoclonal antibody - Tolerx; TRX4

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BTG
  • Developer GlaxoSmithKline; GSK; Tolerx
  • Class Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Graves ophthalmopathy; Multiple sclerosis; Myasthenia gravis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
  • 27 Sep 2018 GlaxoSmithKline completes a phase II trial in Type-1 diabetes mellitus in Belgium (IV) (NCT02000817)
  • 11 Oct 2017 GlaxoSmithKline terminates the phase I TTEDD trial in Type-1 diabetes mellitus in USA and Canada (IV) (NCT00451321)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top